TScan’s Antigen Discovery Platform Enables Tolerizing Therapies Through Identification of CD8⁺ and CD4⁺ T cell Targets
- Introduction to TargetScan, a cell-based, unbiased platform that pairs naturally presented antigens with their cognate TCRs
- Demonstrating TargetScan’s ability to identify both CD8⁺ and CD4⁺ T cell targets in example indications such as ankylosing spondylitis, birdshot uveitis, scleroderma, and ulcerative colitis
- Exploring novel biologically validated targets that enable antigen-specific tolerizing therapies in indications such as ankylosing spondylitis